Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.date.accessioned | 2021-09-06T04:06:46Z | - |
dc.date.available | 2021-09-06T04:06:46Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103912 | - |
dc.description.abstract | Purpose Activating mutation of the KRAS oncogene is an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, KRAS mutation as a prognostic factor of survival outcome remains controversial in CRC, independent of anti-EGFR therapies. Materials and Methods We conducted a retrospective analysis of 103 CRC patients who were available for evaluation of KRAS mutation status. None of the patients analyzed had received anti-EGFR therapies. The role of KRAS mutation status was evaluated as a predictive factor for oxaliplatin or irinotecan and as a prognostic factor in CRC patients who did not receive anti-EGFR therapies. Results Mutations in KRAS were observed in 48.5% of patients. The response for oxaliplatin-(p=0.664) and irinotecan-based (p=0.255) cytotoxic chemotherapy did not differ according to the KRAS mutation status. In addition, no significant difference in progression free survival (PFS; oxaliplatin, p=0.583 and irinotecan, p=0.426) and overall survival (OS; p=0.258) was observed between the wild and mutant type of the KRAS gene. In univariate and multivariate analyses, KRAS mutations did not have a major prognostic value regarding PFS (oxaliplatin: hazard ratio, 0.892; 95% confidence interval [CI], 0.590 to 1.347; p=0.586 and irinotecan: hazard ratio, 0.831; 95% CI, 0.524 to 1.319.; p=0.433) or OS (hazard ratio, 0.754; 95% CI, 0.460 to 1.236; p=0.263). In addition, anti-vascular endothelial growth factor therapies did not affect PFS to oxaliplatin or irinotecan and OS. Conclusion KRAS mutation is not a prognostic marker for PFS to oxaliplatin or irinotecan and OS in CRC patients who did not receive anti-EGFR therapies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | ADVANCED COLORECTAL-CANCER | - |
dc.subject | KIRSTEN RAS MUTATIONS | - |
dc.subject | K-RAS | - |
dc.subject | P53 | - |
dc.subject | PROGNOSIS | - |
dc.subject | SURVIVAL | - |
dc.subject | STAGE | - |
dc.subject | TUMORIGENESIS | - |
dc.subject | FLUOROURACIL | - |
dc.subject | ASSOCIATION | - |
dc.title | Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.contributor.affiliatedAuthor | Shin, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.4143/crt.2013.45.1.55 | - |
dc.identifier.scopusid | 2-s2.0-84879074702 | - |
dc.identifier.wosid | 000316979800007 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.45, no.1, pp.55 - 62 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 45 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 55 | - |
dc.citation.endPage | 62 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001753152 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ADVANCED COLORECTAL-CANCER | - |
dc.subject.keywordPlus | KIRSTEN RAS MUTATIONS | - |
dc.subject.keywordPlus | K-RAS | - |
dc.subject.keywordPlus | P53 | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | STAGE | - |
dc.subject.keywordPlus | TUMORIGENESIS | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordAuthor | KRAS | - |
dc.subject.keywordAuthor | Anti-EGFR | - |
dc.subject.keywordAuthor | Colorectal neoplasms | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.